FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225288519> ?p ?o ?g. }

• W4225288519 endingPage "e28722" @default.
• W4225288519 startingPage "e28722" @default.
• W4225288519 abstract "Rationale: The ongoing coronavirus pandemic has caused severe acute respiratory syndrome, posing a significant challenge for patients receiving immunotherapy for immune-mediated inflammatory diseases. As of January 2022, immunosuppressants such as tumor necrosis factor inhibitors (anti-TNFα) and azathioprine are inadvisable for an infectious disease caused by the SARS-CoV-2 virus (COVID-19). We continued infliximab as a second induction dose nine days after the onset of COVID-19 symptoms in a patient with acute severe ulcerative colitis. Patient concerns: We report the case of a 34-year-old male with 6 to 8 times bloody diarrhea, fever, and cramping abdominal pain. Ulcerative colitis was diagnosed 6 months earlier and treated with mesalamine 80 mg/kg/day and azathioprine 2.5 mg/kg/day. The patient had never undergone surgery before. Sigmoidoscopy revealed multiple ulcerations and spontaneous bleeding, and the colon samples tested negative for cytomegalovirus and Clostridium difficile. However, intravenous corticosteroids did not induce remission. A nasopharyngeal swab tested positive for SARS-CoV-2. Diagnosis: Acute severe ulcerative colitis and SARS-CoV-2 (COVID-19) pneumonia. Interventions: The second loading dose of infliximab was administered nine days after the diagnosis of COVID-19. Outcome: The patient completed infliximab induction at a dose of 5 mg/kg at weeks 0, 2, and 6, with no complications. Lessons: It is unclear whether anti-TNF-α treatment improves or deteriorates COVID-19 patient outcomes, and this case demonstrates that infliximab can be used safely. Current guidelines make a weak recommendation to avoid using anti-TNFα agents in the presence of acute COVID-19 infection. There is an urgent need for research on biologics therapy." @default.
• W4225288519 created "2022-05-05" @default.
• W4225288519 creator A5026104098 @default.
• W4225288519 creator A5038337658 @default.
• W4225288519 creator A5048700466 @default.
• W4225288519 creator A5069827770 @default.
• W4225288519 date "2022-01-28" @default.
• W4225288519 modified "2023-09-26" @default.
• W4225288519 title "SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis" @default.
• W4225288519 cites W2013665866 @default.
• W4225288519 cites W2075484418 @default.
• W4225288519 cites W2093099981 @default.
• W4225288519 cites W2138119117 @default.
• W4225288519 cites W2146101488 @default.
• W4225288519 cites W2148497851 @default.
• W4225288519 cites W2220275977 @default.
• W4225288519 cites W2404993428 @default.
• W4225288519 cites W2473016454 @default.
• W4225288519 cites W2576459939 @default.
• W4225288519 cites W2602321146 @default.
• W4225288519 cites W2736458610 @default.
• W4225288519 cites W2891495287 @default.
• W4225288519 cites W2919081348 @default.
• W4225288519 cites W2976362764 @default.
• W4225288519 cites W2991207961 @default.
• W4225288519 cites W3003217347 @default.
• W4225288519 cites W3005036059 @default.
• W4225288519 cites W3008443627 @default.
• W4225288519 cites W3008827533 @default.
• W4225288519 cites W3009314935 @default.
• W4225288519 cites W3009567932 @default.
• W4225288519 cites W3009859788 @default.
• W4225288519 cites W3014561994 @default.
• W4225288519 cites W3015718611 @default.
• W4225288519 cites W3016274830 @default.
• W4225288519 cites W3016615702 @default.
• W4225288519 cites W3016661132 @default.
• W4225288519 cites W3016936957 @default.
• W4225288519 cites W3017914302 @default.
• W4225288519 cites W3019235900 @default.
• W4225288519 cites W3031622391 @default.
• W4225288519 cites W3035133049 @default.
• W4225288519 cites W3042928294 @default.
• W4225288519 cites W3043397448 @default.
• W4225288519 cites W3044087915 @default.
• W4225288519 cites W3044827539 @default.
• W4225288519 cites W3083625900 @default.
• W4225288519 cites W3092577165 @default.
• W4225288519 cites W3107654509 @default.
• W4225288519 cites W3115410759 @default.
• W4225288519 cites W3133714871 @default.
• W4225288519 cites W3156276993 @default.
• W4225288519 cites W3164666168 @default.
• W4225288519 cites W3181402861 @default.
• W4225288519 cites W3183586776 @default.
• W4225288519 cites W4210642183 @default.
• W4225288519 cites W4210662453 @default.
• W4225288519 cites W4293777482 @default.
• W4225288519 doi "https://doi.org/10.1097/md.0000000000028722" @default.
• W4225288519 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35089243" @default.
• W4225288519 hasPublicationYear "2022" @default.
• W4225288519 type Work @default.
• W4225288519 citedByCount "3" @default.
• W4225288519 countsByYear W42252885192022 @default.
• W4225288519 countsByYear W42252885192023 @default.
• W4225288519 crossrefType "journal-article" @default.
• W4225288519 hasAuthorship W4225288519A5026104098 @default.
• W4225288519 hasAuthorship W4225288519A5038337658 @default.
• W4225288519 hasAuthorship W4225288519A5048700466 @default.
• W4225288519 hasAuthorship W4225288519A5069827770 @default.
• W4225288519 hasBestOaLocation W42252885191 @default.
• W4225288519 hasConcept C126322002 @default.
• W4225288519 hasConcept C141071460 @default.
• W4225288519 hasConcept C17991360 @default.
• W4225288519 hasConcept C2775862500 @default.
• W4225288519 hasConcept C2776667177 @default.
• W4225288519 hasConcept C2776760755 @default.
• W4225288519 hasConcept C2777138892 @default.
• W4225288519 hasConcept C2777914695 @default.
• W4225288519 hasConcept C2778260677 @default.
• W4225288519 hasConcept C2779134260 @default.
• W4225288519 hasConcept C2780479503 @default.
• W4225288519 hasConcept C71924100 @default.
• W4225288519 hasConcept C90924648 @default.
• W4225288519 hasConceptScore W4225288519C126322002 @default.
• W4225288519 hasConceptScore W4225288519C141071460 @default.
• W4225288519 hasConceptScore W4225288519C17991360 @default.
• W4225288519 hasConceptScore W4225288519C2775862500 @default.
• W4225288519 hasConceptScore W4225288519C2776667177 @default.
• W4225288519 hasConceptScore W4225288519C2776760755 @default.
• W4225288519 hasConceptScore W4225288519C2777138892 @default.
• W4225288519 hasConceptScore W4225288519C2777914695 @default.
• W4225288519 hasConceptScore W4225288519C2778260677 @default.
• W4225288519 hasConceptScore W4225288519C2779134260 @default.
• W4225288519 hasConceptScore W4225288519C2780479503 @default.
• W4225288519 hasConceptScore W4225288519C71924100 @default.
• W4225288519 hasConceptScore W4225288519C90924648 @default.
• W4225288519 hasIssue "4" @default.

• next